Prostrakan, the company that eventually acquired the rights to PSK-3841 (aka RU), ran two clinical trials in humans in the early to mid 2000s. The first was a PhI (n=30) and the second was a randomised and placebo controlled PhII (n=120), but results were never published, nor did a pivotal trial start.
Now we have (non-)steroidal antiandrogens with published data, which are fluridil, clascoterone (CB-03-01) and pyrilutamide.
Comment